Global animal health leader adopts ³Ô¹Ï±¬ÁÏ Vault Clinical and ³Ô¹Ï±¬ÁÏ Vault RIM
for greater efficiency, visibility, and speed<\/i><\/p>\n
BARCELONA, Spain \u2014 14 Feb. 2024 \u2014<\/strong> ³Ô¹Ï±¬ÁÏ Systems<\/a> (NYSE: VEEV) today announced that Boehringer Ingelheim has selected ³Ô¹Ï±¬ÁÏ Vault Clinical<\/a> and ³Ô¹Ï±¬ÁÏ Vault RIM<\/a> applications as its technology foundation for clinical and regulatory management in its animal health business unit. By adopting unified applications on a single platform, Boehringer Ingelheim can streamline clinical execution to speed development of new medicines that help animals live healthier and happier lives.<\/p>\n \u201c³Ô¹Ï±¬ÁÏ Vault Clinical and ³Ô¹Ï±¬ÁÏ Vault RIM will help us drive higher operational efficiency across functions while providing the insights for data-driven decision making,\u201d said Marcus Gravendyck, head of global regulatory affairs and pharmacovigilance, Animal Health at Boehringer Ingelheim. \u201cThis will allow us to execute and innovate faster to improve the lives of animals.\u201d<\/p>\n Boehringer Ingelheim will use ³Ô¹Ï±¬ÁÏ Vault CTMS<\/a> in its animal health business unit to manage and monitor trials and ³Ô¹Ï±¬ÁÏ Vault eTMF<\/a> for real-time inspection readiness, visibility, and control. The company will also use Vault RIM applications, including ³Ô¹Ï±¬ÁÏ Vault Registrations<\/a>, ³Ô¹Ï±¬ÁÏ Vault Submissions<\/a>, and ³Ô¹Ï±¬ÁÏ Vault Submissions Archive<\/a> for advanced regulatory processes. Connecting these applications on a single cloud platform will enable real-time access to data and seamless information exchange.<\/p>\n \u201cBoehringer Ingelheim is driving innovation to accelerate the development of new treatments for animals,\u201d said Thomas Reith, corporate vice president, IT research, development, and medicine at Boehringer Ingelheim. \u201cBy establishing a centralized and digital foundation with ³Ô¹Ï±¬ÁÏ, we can deliver a better user experience for our teams, and offer lean, end-to-end processes for speed and agility.\u201d<\/p>\n \u201cWe\u2019re proud to partner with Boehringer Ingelheim in animal health to simplify their clinical development and regulatory processes,\u201d said Stefan Jahnecke, vice president of animal health strategy at ³Ô¹Ï±¬ÁÏ. \u201c³Ô¹Ï±¬ÁÏ Vault Clinical and ³Ô¹Ï±¬ÁÏ Vault RIM will help Boehringer Ingelheim increase data integrity and provide the visibility to quickly adapt to changing business requirements.\u201d<\/p>\n Vault Clinical and Vault RIM are part of ³Ô¹Ï±¬ÁÏ Development Cloud<\/a>, the technology foundation for product development across clinical, regulatory, quality, and safety. To learn more, visit veeva.com\/eu\/DevelopmentCloud<\/a>.<\/p>\n About ³Ô¹Ï±¬ÁÏ Systems<\/strong> ³Ô¹Ï±¬ÁÏ Forward-looking Statements<\/strong> ###<\/p>\n
\n³Ô¹Ï±¬ÁÏ is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 1,000 customers, ranging from the world\u2019s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation<\/a>, ³Ô¹Ï±¬ÁÏ is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>.<\/p>\n
\nThis release contains forward-looking statements regarding ³Ô¹Ï±¬ÁÏ\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2023, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.<\/p>\n